02.23.26 -- This Industrial Fungus Has Protein Expression Promise For Pharma

Selecting and engineering the right cell line is not simply a technical milestone; it is a strategic decision that shapes cost of goods, development timelines, and the overall probability of success.

Monoclonal antibody manufacturing is advancing to boost efficiency, cut costs, and expand access, driven by innovation, demand, and the rise of biosimilars.

The top five common cell line development pitfalls — scalability, stability, complexity, analytics, and tech transfer — can be avoided with experienced partners and integrated, predictive strategies.

Maximize your lab’s efficiency without sacrificing space. Discover how triple-stack incubators help scale operations, run multiple experiments, and streamline workflows within a compact footprint.

Explore how gene editing tools and HLA-F technologies are revolutionizing hypoimmunogenic cell development for scalable allogeneic therapies.

Learn how Tangential Flow Depth Filtration (TFDF) enhances viral vector production, streamlining the clarification process and increasing efficiency and yield for LV and AAV manufacturing.

Examine temperature effects on product titer, automated cell culture development workflow, maximizing product life-cycle efficiency with the right DOE strategy, and effective data management.

Non-viral gene editing is a powerful method for cell therapy. See how to address key challenges like cell viability and thermal damage with an innovative approach designed to improve performance.

To maximize the results of viral titer and full capsids, it's necessary to undertake systematic process development and optimization of AAV production. The choice of cell culture medium is foundational.